CheckOrphan – Rare Diseases & Orphan Products

Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights
Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance
Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities
We Might Finally Know How Alzheimer’s Spreads Through The Brain
Stoke Therapeutics Announces $40 Million Series A Financing to Create Pioneering New Medicines that Restore Gene Expression in Severe Genetic Diseases

Companies are increasingly recognizing the importance of Electronic Data Room

These colleges give another variety of the best way to study to learners.

Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights

Tuesday, January 9, 2018

Bagsværd, Denmark – Novo Nordisk today confirms that it made a proposal on 22 December 2017 to acquire Ablynx for €28.00 per share in cash and one CVR with total potential cash payments over time of up to €2.50 per share. This proposal implies a total equity valuation of approximately €2.6 billion1 for...
Stoke Therapeutics Announces $40 Million Series A Financing to Create Pioneering New Medicines that Restore Gene Expression in Severe Genetic Diseases

Friday, January 5, 2018

BEDFORD, Mass. – Stoke Therapeutics, Inc, a new company working to increase gene expression to treat a wide array of diseases caused by genetic insufficiency, announced that it has completed a $40 million Series A financing to support the further advancement of multiple pre-clinical development programs. The Series A round...

More News

Rare Conversations: Sheri & Stephanie

Rare Conversations: Kendra & Preston

Overview on Understanding Mitochondria?

More Videos

Ubiquitin Disorder

Pseudo-Zellweger syndrome

Pseudoxanthoma elasticum- dominant form

Pterygium colli mental retardation digital anomalies

More Rare Diseases

Rare DiseasesFollow

CheckOrphan is the leading #news and information platform dedicated to #rarediseases and #orphandrugs

Rare Diseases@CheckOrphan·

14 Jan

Have you already checked #CheckOrphan? Learn about #RareDiseases, their #symptoms and #treatments at http://5.102.147.165/diseases

Reply on Twitter 1217099762199093248 Retweet on Twitter 12170997621990932481 Like on Twitter 12170997621990932482 Twitter 1217099762199093248

Rare Diseases@CheckOrphan·

10 Jan

My week on Twitter 🎉: 2 Mentions, 13 Likes, 2 Retweets, 105 Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=64bb720613b5a38dd07f5be4

Reply on Twitter 1215712320464326661 Retweet on Twitter 1215712320464326661 Like on Twitter 12157123204643266611 Twitter 1215712320464326661

Rare Diseases@CheckOrphan·

10 Jan

Learn more about #RareDiseases and #OrphanDrugs on #CheckOrphan. Join our #FreeNewsletter at http://5.102.147.165/news

Reply on Twitter 1215650197625286657 Retweet on Twitter 1215650197625286657 Like on Twitter 12156501976252866572 Twitter 1215650197625286657

Rare Diseases@CheckOrphan·

9 Jan

Have you already checked #CheckOrphan? Learn about #RareDiseases, their #symptoms and #treatments at http://5.102.147.165/diseases

Reply on Twitter 1215287706684661761 Retweet on Twitter 12152877066846617611 Like on Twitter 12152877066846617613 Twitter 1215287706684661761

Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights

Alnylam and Sanofi Enter into Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance

Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities

We Might Finally Know How Alzheimer’s Spreads Through The Brain

Stoke Therapeutics Announces $40 Million Series A Financing to Create Pioneering New Medicines that Restore Gene Expression in Severe Genetic Diseases

Latest News

Videos

Rare disease spotlight

Twitter